Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03684460 · ClinicalTrials.gov registry record · NA

Daytime Bright Light, Circadian Abnormalities, and Delirium in Medical ICU Patients

A NA study of Circadian Rhythm Disorders, sponsored by Yale University.

Completed
Registry status
NA
Development phase
68
Enrollment target
1
Study location

NCT03684460: Completed NA study of Circadian Rhythm Disorders, sponsored by Yale University.

NCT03684460 is a NA study of Circadian Rhythm Disorders that has completed, run by Yale University. The registered enrollment target is 68 participants, below the 109-participant average among 7 other Circadian Rhythm Disorders trials with a reported enrollment target (38% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03684460, a NA study of Circadian Rhythm Disorders, has completed, sponsored by Yale University.

COMPLETED
Registry status
NA
Development phase
68 participants
Enrollment target
1
Study location

Study Summary

To determine if daytime bright light will promote circadian alignment and shorten or prevent delirium.

Primary Outcome

The primary circadian outcome will be the proportion of daytime activity out of total activity (daytime proportion). Rest-activity patterns will be measured with the Actiwatch Spectrum (Philips Healthcare, Netherlands) set at 30-second epochs and placed on the patient's wrist. Enrolled patients who do not stay in the MICU through 13:00 of Study Day 2 will be excluded from all analysis.

Conditions Studied

Interventions

  • DEVICE Daytime Bright Light
  • DEVICE Usual Light

Study Locations (1)

Connecticut

  • Yale New Haven Hospital, York Street Campus - New Haven

Trial Details

FieldValue
Enrollment Target 68 participants
Start Date 2019-07-08
Est. Completion 2024-03-28
Phase NA
Yale University

1,492 total trials

What the finished NCT03684460 record still lists

NCT03684460 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 68 participants, a relatively small participant target, below the 109-participant average among 7 other Circadian Rhythm Disorders trials with a reported enrollment target (38% lower).

The record links to 1 condition, with Circadian Rhythm Disorders appearing as the primary indexed condition, and to 2 interventions - of which Daytime Bright Light is the first listed.

NCT03684460 reports a single indexed study location in Connecticut.

Frequently Asked Questions

What is clinical trial NCT03684460 about?

NCT03684460 is a clinical study titled "Daytime Bright Light, Circadian Abnormalities, and Delirium in Medical ICU Patients". To determine if daytime bright light will promote circadian alignment and shorten or prevent delirium.

What is the current status of trial NCT03684460?

This trial is currently completed. It is a NA study. The enrollment target is 68 participants. The study started on 2019-07-08. Estimated completion is 2024-03-28.

What conditions does trial NCT03684460 study?

This clinical trial studies the following conditions: Circadian Rhythm Disorders.

What interventions are being tested in trial NCT03684460?

The interventions under investigation include: Daytime Bright Light (DEVICE), Usual Light (DEVICE).

Who is sponsoring clinical trial NCT03684460?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03684460 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Circadian Rhythm Disorders

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02044497 · 68 participants · Phase 4

    Population Pharmacokinetics and Pharmacogenomics of Oral Oxycodone in Pediatric Surgical Patients

  • NCT03779854 · 68 participants · Phase 2

    Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant

  • NCT03821246 · 68 participants · Phase 2

    Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy

  • NCT04115514 · 68 participants · Phase 2

    Treatment of ARDS With Instilled T3

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03684460, the US trial registry maintained by the National Library of Medicine. NCT03684460 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.